RNS Number : 4714G

Deepverge PLC

26 July 2021

26 July 2021

AIM share code: DVRG

Deepverge PLC

("Deepverge" or "Company")

Result of Annual General Meeting

Following today's Annual General Meeting ("AGM"), convened by the Notice of AGM dated 2 July 2021, DeepVerge plc is pleased to announce that all resolutions set out in the Notice of AGM were approved by shareholders.

The results of the poll for each resolution were as follows:

            Resolution                   For       % For    Against    % Against   Withheld 
 1. The Company's annual 
  accounts for the 12 months 
  ended 31 December 2020, 
  together with the directors' 
  report and auditor's report 
  thereon, be received and 
  adopted.                           34,372,474     99.9%     9,700      0.028%     28,951 
                                    ------------  -------  ---------  ----------  --------- 
 2. To re-appoint Jeffreys 
  Henry LLP as auditors.              34,380,263    99.9%     1,611     0.005%      29,251 
                                    ------------  -------  ---------  ----------  --------- 
 3. To determine the remuneration 
  of the auditors.                   34,372,752    99.9%     11,044     0.032%      27,329 
                                    ------------  -------  ---------  ----------  --------- 
 4. To re-elect Nigel Burton 
  as a director of the Company.      34,368,338    99.9%     13,611     0.040%      29,176 
                                    ------------  -------  ---------  ----------  --------- 
 5. To re-elect Camillus 
  Glover as a director of 
  the Company.                       34,368,129    99.9%     13,820     0.040%      29,176 
                                    ------------  -------  ---------  ----------  --------- 
 6. To authorise the directors 
  to allot shares pursuant 
  to Section 551 of the 
  Companies Act 2006.                34,143,623    99.2%     76,963     0.224%     190,539 
                                    ------------  -------  ---------  ----------  --------- 
 7. To authorise the directors 
  to allot equity securities 
  (within the meaning of 
  section 560 of the Companies 
  Act 2006) for cash as 
  if section 561 of the 
  Companies Act 2006 did 
  not apply to such allotment.       34,049,883     99.0%    161,722     0.470%     199,520 
                                    ------------  -------  ---------  ----------  --------- 

As at the date of the AGM, the number of issued ordinary shares of the Company was 215,156,378 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, on a poll every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

Following today's AGM result, a short video will be posted on the Company's website: https://www.deepverge.com/investors

For further information please visit https://www.deepverge.com/or contact:


                                                   +44 (0) 7340 055 
 DeepVerge plc              Gerard Brandon, CEO     648 
 SPARK Advisory Partners 
  Limited                   Neil Baldwin/Andrew 
  (Nominated Adviser)        Emmott                +44 (0) 113 370 8974 
 Turner Pope Investments 
  (TPI) Limited             Andy Thacker/James 
  (Broker)                   Pope                  +44 (0) 20 3621 4120 

About DeepVerge

DeepVerge plc is a vertically integrated business. It's core skin and human testing technology is built on a clinical based eco-system. Collaboration partners in artificial intelligence, clinical research, medical device and life science contribute to the service management platform. This allows skin-care, health-care, nutritional, pharmaceutical manufacturers and cosmetic companies to test consumer products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company's own skin-care range of products and cannabinoid oils (CBD) sources have been used to test the platform that combines data analytics with access to therapeutic operational expertise offering client solutions ranging from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our laboratory grown living human tissue (Labskin).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 26, 2021 07:25 ET (11:25 GMT)

Deepverge (LSE:DVRG)
Gráfica de Acción Histórica
De Sep 2021 a Oct 2021 Haga Click aquí para más Gráficas Deepverge.
Deepverge (LSE:DVRG)
Gráfica de Acción Histórica
De Oct 2020 a Oct 2021 Haga Click aquí para más Gráficas Deepverge.